Last reviewed · How we verify
Menactra®: Meningococcal Polysaccharide Diphtheria Conjugate
Menactra®: Meningococcal Polysaccharide Diphtheria Conjugate is a Biologic drug developed by Sanofi Pasteur, a Sanofi Company. It is currently in Phase 2 development. Also known as: Menactra®.
At a glance
| Generic name | Menactra®: Meningococcal Polysaccharide Diphtheria Conjugate |
|---|---|
| Also known as | Menactra® |
| Sponsor | Sanofi Pasteur, a Sanofi Company |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa (PHASE3)
- Study of a Quadrivalent Meningococcal Conjugate Vaccine as a Single Dose Compared With a Single Dose of a Meningococcal Reference Vaccine in Children, Adolescents, and Adults 2 to 55 Years of Age (PHASE3)
- Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe (PHASE3)
- Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adults, Adolescents, Children, and Toddlers in India and Healthy Adolescents and Children in the Republic of South Africa (PHASE3)
- Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US (PHASE3)
- Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers (PHASE3)
- Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers (PHASE3)
- Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the Russian Federation and Mexico (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Menactra®: Meningococcal Polysaccharide Diphtheria Conjugate CI brief — competitive landscape report
- Menactra®: Meningococcal Polysaccharide Diphtheria Conjugate updates RSS · CI watch RSS
- Sanofi Pasteur, a Sanofi Company portfolio CI
Frequently asked questions about Menactra®: Meningococcal Polysaccharide Diphtheria Conjugate
What is Menactra®: Meningococcal Polysaccharide Diphtheria Conjugate?
Menactra®: Meningococcal Polysaccharide Diphtheria Conjugate is a Biologic drug developed by Sanofi Pasteur, a Sanofi Company.
Who makes Menactra®: Meningococcal Polysaccharide Diphtheria Conjugate?
Menactra®: Meningococcal Polysaccharide Diphtheria Conjugate is developed by Sanofi Pasteur, a Sanofi Company (see full Sanofi Pasteur, a Sanofi Company pipeline at /company/sanofi).
Is Menactra®: Meningococcal Polysaccharide Diphtheria Conjugate also known as anything else?
Menactra®: Meningococcal Polysaccharide Diphtheria Conjugate is also known as Menactra®.
What development phase is Menactra®: Meningococcal Polysaccharide Diphtheria Conjugate in?
Menactra®: Meningococcal Polysaccharide Diphtheria Conjugate is in Phase 2.
Related
- Manufacturer: Sanofi Pasteur, a Sanofi Company — full pipeline
- Also known as: Menactra®
- Compare: Menactra®: Meningococcal Polysaccharide Diphtheria Conjugate vs similar drugs
- Pricing: Menactra®: Meningococcal Polysaccharide Diphtheria Conjugate cost, discount & access